Tislelizumab before and after surgery for KRAS-mutated lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests whether adding the immunotherapy drug tislelizumab before and after surgery can help people with a specific type of lung cancer (non-squamous NSCLC with a KRAS mutation) that is stage 2 or 3. It aims to improve treatment outcomes by targeting the cancer early.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have stage 2 or 3 (with N2 node involvement) non-squamous non-small cell lung cancer.
- Your cancer must have a KRAS gene mutation.
- You cannot have received any prior treatment for this lung cancer (like chemotherapy, radiation, or immunotherapy).
- You must be healthy enough for surgery and able to receive platinum-based chemotherapy before and after surgery.
- You must not have active autoimmune disease or lung conditions like interstitial lung disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether giving a combination of the immunotherapy drug tislelizumab and chest radiation before surgery can improve outcomes for people with early-stage, operable lung cancer. The goal is to find out if this approach helps shrink the tumor and makes surgery more effective.
This trial tests a combination of three drugs (trametinib, anlotinib, and tislelizumab) for people with KRAS-mutant non-small cell lung cancer that has progressed after one prior treatment. The goal is to see if this combination can shrink tumors or slow cancer growth.
This trial tests a drug called Tislelizumab (an immunotherapy) combined with chemotherapy for people with advanced NSCLC who have already been helped by a different immunotherapy. It's a second-line option for those who did well on their first immunotherapy but now need another treatment.
This trial tests whether a drug called tislelizumab, given after surgery, can help prevent lung cancer from coming back. It is for people with stage I non-small cell lung cancer who have certain high-risk features and a protein called PD-L1 on their tumor cells.
This trial tests a combination of three drugs (tislelizumab, anlotinib, and standard chemotherapy) given before and after surgery for people with stage II to IIIB non-small cell lung cancer that does not have certain gene mutations. The goal is to see if this approach can improve outcomes for patients who can have their tumor removed.
This trial tests a combination of immunotherapy (tislelizumab) followed by surgery and radiation for people with a specific type of advanced lung cancer (N3 stage NSCLC). The goal is to see if this approach can shrink tumors and improve outcomes.
Hear when a new Lung Cancer, Non-Small Cell trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.